• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Concise Commentary: Second Line Is Not Second Best-Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis.

作者信息

Rivière Pauline, Laharie David, Marteau Philippe

机构信息

Department of Hepatogastroenterology and Digestive Oncology, Haut-Lévêque Hospital, CHU de Bordeaux, Bordeaux, France.

Sorbonne Université - INSERM-ERL 1157, CHU Saint-Antoine 27 - UMR7203 - Saint Antoine IBD Network, APHP, Hôpital Saint Antoine, Paris, France.

出版信息

Dig Dis Sci. 2020 Feb;65(2):581-582. doi: 10.1007/s10620-019-05788-z.

DOI:10.1007/s10620-019-05788-z
PMID:31489565
Abstract
摘要

相似文献

1
Concise Commentary: Second Line Is Not Second Best-Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis.简明评论：二线治疗并非次优选择——牛津标准在急性重度溃疡性结肠炎管理中的持续有效性
Dig Dis Sci. 2020 Feb;65(2):581-582. doi: 10.1007/s10620-019-05788-z.
2
Colectomy rate in acute severe ulcerative colitis in the infliximab era.英夫利昔单抗时代急性重症溃疡性结肠炎的结肠切除术发生率。
Dig Liver Dis. 2008 Oct;40(10):821-6. doi: 10.1016/j.dld.2008.03.014. Epub 2008 May 9.
3
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.英夫利昔单抗治疗溃疡性结肠炎：2000年至2006年牛津地区的治疗结果
Aliment Pharmacol Ther. 2007 May 1;25(9):1055-60. doi: 10.1111/j.1365-2036.2007.03300.x.
4
Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy.根据2011年欧洲克罗恩病和结肠炎组织（ECCO）-欧洲儿科胃肠病、肝病和营养学会（ESPGHAN）指南管理儿童急性重症溃疡性结肠炎：英夫利昔单抗作为挽救治疗的疗效
Dig Liver Dis. 2015 Jun;47(6):455-9. doi: 10.1016/j.dld.2015.01.156. Epub 2015 Feb 4.
5
Current management of severe ulcerative colitis.重度溃疡性结肠炎的当前管理
Nat Clin Pract Gastroenterol Hepatol. 2007 Feb;4(2):92-101. doi: 10.1038/ncpgasthep0687.
6
Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada.英夫利昔单抗治疗溃疡性结肠炎：术前治疗对不列颠哥伦比亚省结肠切除术率和处方实践的影响，加拿大。
Dis Colon Rectum. 2014 Jan;57(1):83-90. doi: 10.1097/DCR.0000000000000003.
7
Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review.抗 TNF 治疗是否能减少溃疡性结肠炎的手术需求？系统评价。
Curr Drug Targets. 2011 Sep;12(10):1440-7. doi: 10.2174/138945011796818153.
8
Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.英夫利昔单抗作为全身用糖皮质激素难治性重度溃疡性结肠炎住院患者的挽救治疗。
Dig Surg. 2008;25(5):383-6. doi: 10.1159/000170882. Epub 2008 Nov 13.
9
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.英夫利昔单抗三剂量诱导方案治疗重度糖皮质激素难治性溃疡性结肠炎：早期和晚期结局及结肠切除术的预测因素
J Crohns Colitis. 2014 Aug;8(8):852-8. doi: 10.1016/j.crohns.2014.01.006. Epub 2014 Jan 25.
10
Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.英夫利昔单抗或环孢素治疗后溃疡性结肠炎患者的结肠切除术发生率：一项系统文献综述
Eur J Gastroenterol Hepatol. 2016 Apr;28(4):369-82. doi: 10.1097/MEG.0000000000000568.

本文引用的文献

1
Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates.急性重度溃疡性结肠炎：牛津标准不再预测住院期间结肠切除术的发生率。
Dig Dis Sci. 2020 Feb;65(2):576-580. doi: 10.1007/s10620-019-05668-6. Epub 2019 May 15.
2
Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.系统评价：英夫利昔单抗诱导缓解治疗住院急性重度结肠炎患者的疗效和安全性。
Dig Dis Sci. 2019 May;64(5):1119-1128. doi: 10.1007/s10620-018-5407-7. Epub 2018 Dec 7.
3
Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry.
类固醇难治性急性重度溃疡性结肠炎患者术后发病率和死亡率：GETECCU ENEIDA 注册全国多中心研究。
Am J Gastroenterol. 2018 Jul;113(7):1009-1016. doi: 10.1038/s41395-018-0057-0. Epub 2018 May 1.
4
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.《欧洲溃疡性结肠炎诊断与管理循证共识（第三版）。第二部分：当前管理》
J Crohns Colitis. 2017 Jul 1;11(7):769-784. doi: 10.1093/ecco-jcc/jjx009.
5
Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.环孢素或英夫利昔单抗治疗类固醇抵抗性急性重度 UC 患者的长期结局。
Gut. 2018 Feb;67(2):237-243. doi: 10.1136/gutjnl-2016-313060. Epub 2017 Jan 4.
6
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.环孢素与英夫利昔单抗治疗对静脉用类固醇无效的重度溃疡性结肠炎患者的疗效比较：一项平行、开放标签、随机对照试验。
Lancet. 2012 Dec 1;380(9857):1909-15. doi: 10.1016/S0140-6736(12)61084-8. Epub 2012 Oct 10.
7
Predicting outcome in severe ulcerative colitis.预测重度溃疡性结肠炎的预后
Gut. 1996 Jun;38(6):905-10. doi: 10.1136/gut.38.6.905.